prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a childs medication. The most common side effect observed in children in
EndeavorRxs clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a
week, over initially at least 4 consecutive weeks, or as recommended by your childs health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Akilis approach of leveraging technologies designed to directly target the brain establishes a new category of medicine medicine that is validated through clinical trials like a drug or medical device
but experienced like entertainment. Akilis platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical
programs. Driven by Akilis belief that effective medicine can also be fun and engaging, Akilis products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.
Cautionary Note Regarding Forward-looking Statements
This
press release contains forward-looking statements. These forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate,
evaluate, intend, strategy, future, opportunity, plan, may, should, will, would, will be, will continue,
will likely result, and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks
and uncertainties. These forward-looking statements include, without limitation, statements in this press release related to: Akilis expectations regarding FDA clearance of its EndeavorOTC product for adults with ADHD; Akilis
expectations regarding the safety, effectiveness, and ease of access of its EndeavorOTC product across different app stores and mobile devices; Akilis expectations regarding the number of adults with ADHD who can now access EndeavorOTC and
that the results of previous clinical studies will be predictive of future clinical trials or results; and Akilis expectations regarding this new tier of digital medicine. Any forward-looking statements in this press release are based on
managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without limitation, risks and uncertainties related to: uncertainties as to the timing of the tender offer and merger and whether, and if so when, the closing may occur in connection with the